-
Merz offers Xeomin users financial assistance with new programs
GREENSBORO, N.C. — Merz Pharmaceuticals has created two programs to provide financial assistance to patients using its drug for cervical dystonia, the company said Tuesday.
The programs — the Xeomin patient co-payment program and the Xeomin patient assistance program — cover Xeomin (incobotulinumtoxinA), designed to decrease the severity of abnormal head positions and neck pains in patients with the disease, which causes muscle contractions resulting in repetitive movements and abnormal postures.
-
Keryx to present phase-3 clinical data for Zerenex at conference
NEW YORK — Late-stage clinical trial data for a Keryx Biopharmaceuticals drug to treat kidney disease will be presented at a medical conference in Las Vegas.
Keryx said Monday that phase-3 data for the drug Zerenex (ferric citrate), a drug for abnormally high phosphate levels in patients with end-stage kidney disease on dialysis, will be presented at the upcoming National Kidney Foundation spring clinical meetings in April.
The company announced “positive” results from a phase-3 trial of the drug in November.